4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium
Following discontinuation of ERT, AGA activity was stable at 14-fold mean normal level through week…
Embracing AI while Keeping an Eye Out for FraudÂ
ScienceLogicâ„¢ Cuts Complexity and Accelerates IT Performance with Skylarâ„¢ One Updates
Embracing the Three ‘R’s of Quantum
Stockman’s Casino Selects Quick Custom Intelligence Enterprise Platform